KALY Kali Inc.

KALY Gives Veterans 10 Percent Discount On Hemp4mula CBD Gum and 20 Percent Discount to All Over Memorial Day Weekend

KALY Gives Veterans 10 Percent Discount On Hemp4mula CBD Gum and 20 Percent Discount to All Over Memorial Day Weekend

Hemp4mula CBD Gum Available Through

Memorial Day 20% Discount Available to All Now Through May 29th

DALLAS, May 24, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE --  Kali-Extracts (aka Kali, Inc.) (USOTC: KALY)  (“KALY”) today announced its Hemp4mula CBD Gum available to all U.S. Veterans from here forward at a 10% discount. Hemp4mula is available online at the Ecommerce site hosted by North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”). USMJ has launched a Veteran Discount Program called Operation Patriotic Salute extending a 10% discount on all CBD and Cannabis Essentials available on their website . Also, now through May 29th, in honor of the Memorial Daly Celebration, USMJ is offering a 20% discount to everybody on all CBD and Cannabis Essentials.

Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments



In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. KALY owns and operates a U.S. Patent For Cannabis Extraction. In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds.  KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy.  Separately, to generate revenue in parallel while ongoing research is conducted, KALY is launching a line of CBD infused consumer products of which Hemp4mula Gum is the first.  Hemp4mula Gummies are coming soon as well as HempTantation Sunscreen. 



To learn more about the company visit 



This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.



CONTACT:

Frederick Ferri



(214) 210-0459

A photo accompanying this announcement is available at

EN
24/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kali Inc.

 PRESS RELEASE

CORRECTION FROM SOURCE: KALY Exits Cannabis Business With Shareholder ...

This document corrects and replaces the press release that was issued by Kali Inc. (OTC Pink: KALY) (“KALY”) today July 16, 2020 at 11:24 am ET. The release below replaces the entirety of the previous release, as the incorrect release was sent.The corrected press release follows in full below:Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali, Inc. (OTC Pink: KALY) ("KALY") today announced a deal in the works to sell its cannabis execration subsidiary, NCM Biotech, to PAO Group, Inc. (OTC Pink: PAOG) in exchange for common shares of PAOG that will in turn be issued to KALY shareholders in ...

 PRESS RELEASE

KALY Calls for Partners on Patented Technology and Potential COVID-19 ...

Dallas, Texas--(Newsfile Corp. - July 16, 2020) - Kali-Extracts, Inc. (OTC Pink: KALY) (Kali, Inc. dba/Kali-Extracts, Inc.) ("KALY") today issued a call for potential partners that could contribute to the acceleration of evaluating and developing KALY's proprietary CBD formulation developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. Researchers believe the CBD formulation could be effective in the treatment of symptoms resulting from COVID-19.The formulation for the treatment of symptoms associated with C...

 PRESS RELEASE

KALY Previews Investment Commitment Into Its Cannabis Biopharmaceutica...

Dallas, Texas--(Newsfile Corp. - February 3, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY"), today previewed a Letter of Intent (LOI) executed with a third-party investor. The LOI details are anticipated to be released tomorrow. Management indicates the two-stage investment is of substantial magnitude and can meaningfully advance the company's ongoing development of its cannabis biopharmaceutical technology. KALY has a U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical conditi...

 PRESS RELEASE

KALY Patented Cannabis Biotech $50 Million Valuation Supported By Anal...

Dallas, Texas--(Newsfile Corp. - January 31, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today pointed to a on the legal marijuana market projecting the legal marijuana market to reach over $66 Billion in value by 2025 to support a recent $50 Million valuation of KALY's cannabis biotechnology. KALY has U.S. Patented Cannabis Extraction Process it uses to produce proprietary formulations for the treatment of various medical conditions. Grand View Research indicates the growing adoption of cannabis as a pharmaceutical is a substantial driver be...

 PRESS RELEASE

KALY- Kali-Extracts Proprietary CBD Extract Could Offer Coronavirus Re...

Dallas, Texas--(Newsfile Corp. - January 29, 2020) - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (OTC Pink: KALY) ("KALY") today confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY's proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company's U.S. Patented...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch